Nasdaq · Healthcare

Tvardi Therapeutics, Inc. (TVRD)

As-reported financials and recent SEC filings for Tvardi Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

—

Net income

$-18.2M

Net margin

—

Diluted EPS

$-3.26

ROE

-87.0%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	—	$7.1M	$21.0M	$41.9M	$23.0M
Gross profit	—	—	—	—	—
Operating income	$-26.7M	$-28.1M	$-121.5M	$-87.5M	$-89.1M
Net income	$-18.2M	$-29.4M	$-118.5M	$-85.5M	$-88.4M
Diluted EPS	$-3.26	$-3.81	$-8.75	$-6.37	$-6.38

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-11

42026-06-11

42026-06-11

42026-06-11

42026-06-11

8-K2026-06-11

EFFECT2026-05-13

EFFECT2026-05-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on TVRD

Search Tvardi Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.